Latest From Elizabeth Cairns
Argenx has aggressive market expansion plans for Vyvgart. It also has several late-stage challengers in what is becoming a dynamic market.
Pivotal data on the oral BTK inhibitor could enable Novartis to maintain its hold on the urticaria market.
Both groups have posted hits with similar novel antibiotics, and both have a lot riding on commercial success.
INFOGRAPHIC: This overview of the obesity market shows the biggest money-spinners in terms of products and mechanisms, the biggest investors and dealmakers – and looks at how some of the notable current and potential future therapies stack up in the clinic.
The long-delayed accelerated approval of the melanoma T-cell therapy comes a week early, and with a generous label.
An adverse reaction in lanafibranor’s Phase III trial leaves the company even more reliant on the upcoming LEGEND readout.